Home

News

News

News

2021-07-05 10:00:00
Suzhou Caike has successively completed the A-1 round and A-2 rounds of financing, and continues to make efforts in the direction of life sciences and in vitro diagnostics
Suzhou Caike has successively completed the A-1 round and A-2 rounds of financing, and continues to make efforts in the direction of life sciences and in vitro diagnostics
2020-06-01 01:41:38
Laurel Venture Capital has completed the full acquisition of GSNOR inhibitors from Alpine Immune Sciences
Recently, Laurel Venture Capital announced that it has completed the acquisition of Alpine Immune Sciences (NASDAQ:ALPN) GSNOR inhibitor assets. This includes the global patent rights of GSNOR inhibit
2019-09-02 01:40:43
First launch | Citryll raises 15 million euros to develop NETosis inhibitory antibody, Borui Biotech participates in the investment
On July 3, 2019, in the Netherlands, Citryll B.V. announced today that it has completed a round A round of 15 million euros in financing, led by the Dutch biomedical fund BOM Brabant Ventures, and joi
2019-09-02 01:40:00
Path BioAnalytics announces that it has been authorized by Langyu Pharmaceuticals to develop targeted therapeutic drugs for cystic fibrosis
[Beijing time 2019\8\21] Chapel Hill, North Carolina, USA-Path BioAnalytics Inc. (PBA), a precision medicine company focused on the discovery and development of new treatments for respiratory diseases
2018-08-07 01:38:21
The financing of pharmaceutical companies is good, and early investment is particularly hot
Pharmaceutical companies are companies engaged in drug delivery, drug development, and drug processing, excluding companies engaged in medical devices, digital medical treatment, and disease diagnosis

Cangqian Street, Yuhang District, Hangzhou European and American Financial City (EFC), British Centre, T2-805
Post Code: 310000

Contact

Room 805, Building T2, EFC, Yuhang District, Hangzhou

Follow us

Laurel Venture

© 2021

All Rights Reserved.